Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297). Methods PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177 Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25-50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed. Results Fifty-two patients underwent 171 cycles. In 34 patients who co…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These studies have demonstrated wide interpatient variability of renal absorbed dose by a factor of 10, underscoring the importance of dosimetry.”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [61]
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Quality of life research within the EORTC—the EORTC QLQ-C30
Fayers, P., & Bottomley, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00448-8 · Cited by 924
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 424
Sandström, M., Garske-Román, U., Granberg, D., Johansson, S., Widström, C., Eriksson, B., Sundin, A., Lundqvist, H., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107524 · Cited by 287
Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 266
Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193706 · Cited by 219
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Sundlöv, A., Sjögreen-Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T., Bernhardt, P., & Tennvall, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3678-4 · Cited by 209
Cited by
Sjögreen Gleisner, K., Chouin, N., Gabina, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 252
Privé, B. M., Boussihmad, M. A., Timmermans, B., van Gemert, W. A., Peters, S. M. B., Derks, Y. H. W., van Lith, S. A. M., Mehra, N., Nagarajah, J., Heskamp, S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06144-0 · Cited by 198
Nölting, S., Ullrich, M., Pietzsch, J., Ziegler, C. G., Eisenhofer, G., Grossman, A., & Pacak, K. (2019) · Cancers · doi:10.3390/cancers11101505 · Cited by 172
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
“The renal dosimetry threshold has been used by studies to optimize treatment schedules by modifying the administered activity per cycle or number of cycles of (177)Lu-DOTATATE (60,61).”
MethodSundlöv, A., Gleisner, K. S., Tennvall, J., Ljungberg, M. H., Warfvinge, C. F., Holgersson, K., Hallqvist, A., Bernhardt, P., & Svensson, J. B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05786-w · Cited by 106
Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88
“octreotate peptide receptor therapy for neuroendocrine tumors [51].”
BackgroundDosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177 Lu-DOTATATE
Roth, D. R., Gustafsson, J., Warfvinge, C. F., Sundlöv, A., Åkesson, A., Tennvall, J., & Gleisner, K. S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262069 · Cited by 94
“However, the specifics of such a protocol would require detailed consideration of the tumor-to-kidney AD ratios, as well as the risk of hematologic and pituitary toxicity (4,7,16,32).”
BackgroundDosimetry in radionuclide therapy: the clinical role of measuring radiation dose
Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 83
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
Fortunati, E., Argalia, G., Zanoni, L., Fanti, S., & Ambrosini, V. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00967-z · Cited by 78
Geenen, L., Nonnekens, J., Konijnenberg, M., Baatout, S., de Jong, M., & Aerts, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.06.006 · Cited by 79
“Therefore, the doselimiting role of the bone marrow might be of greater importance, as it seems that increasing the injected activity per cycle and/or the number of cycles is associated with increased hematologic toxicities [44].”
BackgroundMethodAccuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
Prete, M. D., Arsenault, F., Saighi, N., Zhao, W., Buteau, F.-A., Celler, A. M., & Beauregard, J. (2018) · EJNMMI Physics · doi:10.1186/s40658-018-0224-9 · Cited by 69
Self-citationHébert, K., Santoro, L., Monnier, M., Castan, F., Berkane, I., Assénat, E., Fersing, C., Gelibert, P., Pouget, J., Bardiès, M., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267023 · Cited by 69
“In our sample, the CumAD by the kidneys never reached 23Gy, which was considered an endpoint in recent PRRT trials ( 19,20 ) and was considered for external-beam radiotherapy.”
BackgroundPersonalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects
Danieli, R., Milano, A., Gallo, S., Veronese, I., Lascialfari, A., Indovina, L., Botta, F., Ferrari, M. E., Cicchetti, A., Raspanti, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020205 · Cited by 76
“In addition, for a few therapies, the first promising signs are emerging, showing that the implementation of treatment planning based on dosimetry brings great benefits for the patients compared to the standard approach [43,116,117].”
BackgroundUrso, L., Nieri, A., Uccelli, L., Castello, A., Artioli, P., Cittanti, C., Marzola, M. C., Florimonte, L., Castellani, M., Bissoli, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041110 · Cited by 64
“April 2016 / December 2026 NCT02754297 [105,113] Personalized PRRT of Neuroendocrine Tumors Phase II Canada NET of any primary origin To Evaluate personalized patient-tailored [177Lu]Lu-DOTATATE RLT.”
BackgroundInfluentialMileva, M., Marin, G., Levillain, H., Artigas, C., Bogaert, C. V., Marin, C., Danieli, R., Deleporte, A., Picchia, S., Stathopoulos, K., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265987 · Cited by 69
Rahmim, A., Brosch-Lenz, J., Fele‐Paranj, A., Yousefirizi, F., Soltani, M., Uribe, C., & Saboury, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1062592 · Cited by 67
The molecular blueprint of targeted radionuclide therapy
Primac, I., Tabury, K., Tasdogan, A., Baatout, S., & Herrmann, K. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01069-z · Cited by 70
“Dose variability has been observed in patients with NETs receiving 177 Lu-DOTATATE, often leading to suboptimal tumour irradiation; analyses have shown an association between higher absorbed doses, frequently unmet with fixed-cycle regimens, and better tumour control 293 .”
Zhang, J., Song, Q., Cai, L., Xie, Y., & Chen, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03181-2 · Cited by 61
Sandström, M., Freedman, N., Fröss‐Baron, K., Kahn, T., & Sundin, A. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00339-2 · Cited by 63
Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
O’Neill, E. S., Kersemans, V., Allen, P. D., Terry, S. Y. A., Torres, J. B., Mosley, M. J., Smart, S., Lee, B. Q., Falzone, N., Vallis, K. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.232934 · Cited by 59
“Importantly, most MRT dosimetry and radiobiology have been based on external-beam radiotherapy (EBRT) data because of a paucity of radiobiologic data on radionuclide therapy (10).”
BackgroundPandit-Taskar, N. D., Iravani, A., Lee, D., Jacene, H. A., Pryma, D. A., Hope, T. A., Saboury, B., Capala, J., & Wahl, R. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262977 · Cited by 66
“However, current clinical activity is limited by the 23- to 28-Gy absorbed dose to the kidneys, based on prior retrospective or prospective dosimetry studies (45,117,118).”
BackgroundBidakhvidi, N. A., Goffin, K. E., Dekervel, J., Baete, K., Nackaerts, K., Clément, P. M., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2021) · Cancers · doi:10.3390/cancers14010129 · Cited by 53
“Subacute grade III/IV hematotoxicity occurred in less than 10% of patients which is comparable with the Rotterdam/NETTER-1 regimen and no severe nephrotoxicity was reported [62].”
BackgroundMethodResultInfluentialAlipour, R., Jackson, P. A., Bressel, M., Hogg, A., Callahan, J., Hicks, R. J., & Kong, G. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06257-6 · Cited by 53
“26-fold increase in the cumulative maximum tumour absorbed dose with promising response rates and favourable tolerance profile compared to a fixed administered activity [13].”
BackgroundGiraudet, A., Kryza, D., Hofman, M. S., Moreau, A., Fizazi, K. S., Fléchon, A., Hicks, R. J., & Tran, B. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211053898 · Cited by 46
di Santo, G., Santo, G., Sviridenko, A., & Virgolini, I. J. (2024) · Theranostics · doi:10.7150/thno.91268 · Cited by 49
Frezza, A., Desport, C., Uribe, C., Zhao, W., Celler, A. M., Després, P., & Beauregard, J. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-0275-6 · Cited by 45
Self-citationAkhavanallaf, A., Peterson, A., Fitzpatrick, K., Roseland, M. E., Wong, K. K., Naqa, I. E., Zaidi, H., & Dewaraja, Y. K. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06252-x · Cited by 48
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
Adant, S., Shah, G. M., & Beauregard, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04499-x · Cited by 45
Self-citationNeuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
Hope, T. A., Pavel, M., & Bergsland, E. K. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00176 · Cited by 50
Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy
Graves, S. A., & Hobbs, R. F. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.008 · Cited by 54
Warfvinge, C. F., Gustafsson, J., Roth, D. R., Tennvall, J., Svensson, J. B., Bernhardt, P., Åkesson, A., Wieslander, E., Sundlöv, A., & Gleisner, K. S. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266991 · Cited by 50
“Logistic regression was used to model the tumor control probability (TCP) by fi tting of the logarithm of the odds ratio (Supplement 4).”
MethodCall to arms: need for radiobiology in molecular radionuclide therapy
Terry, S. Y. A., Nonnekens, J., Aerts, A., Baatout, S., de Jong, M., Cornelissen, B. T., & Pouget, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04334-3 · Cited by 44
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 43
Quantitative 177Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera
Danieli, R., Stella, M., Leube, J., Tran‐Gia, J., Marin, C., Uribe, C., Vanderlinden, B., Reynaert, N., Flamen, P., & Levillain, H. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00586-z · Cited by 47
Dewaraja, Y. K., Mirando, D. M., Peterson, A., Niedbala, J., Millet, J. D., Mikell, J. K., Frey, K. A., Wong, K. K., Wilderman, S. J., & Nelson, A. S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263738 · Cited by 36
“4 Gy/ GBq (2) reported for 2 other studies.”
BackgroundInfluentialKiess, A. P., O’Donoghue, J. A., Uribe, C., Bodei, L., Hobbs, R. F., Hesterman, J. Y., Kesner, A., Sgouros, G., Bäck, T. A., Bardiès, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01241 · Cited by 41
Theranostics and Patient-Specific Dosimetry
Bednarz, B. P. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.03.011 · Cited by 46
Bodei, L., Cremonesi, M., Ferrari, M. E., Mittra, E., Kulkarni, H., Deroose, C. M., Srirajaskanthan, R., Ramage, J. K., Grana, C. M., Botta, F., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268903 · Cited by 41
Yusufaly, T., Roncali, E., Brosch-Lenz, J., Uribe, C., Jha, A. K., Currie, G. M., Dutta, J., Fakhri, G. E., McMeekin, H., Pandit-Taskar, N. D., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267927 · Cited by 42
Staanum, P. F., Frellsen, A. F., Olesen, M. L., Iversen, P., & Arveschoug, A. K. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00422-2 · Cited by 35
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Vergnaud, L., Dewaraja, Y. K., Giraudet, A., Badel, J., & Sarrut, D. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00658-8 · Cited by 40
Hemmingsson, J., Svensson, J. B., Hallqvist, A., Smits, K., Johanson, V., & Bernhardt, P. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265484 · Cited by 33
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy
Gleisner, K. S., Flux, G., Bacher, K., Chiesa, C., de Nijs, R., Kagadis, G. C., Lima, T. V. M., Georgosopoulou, M. L., Gabiña, P. M., Nekolla, S. G., et al. (2023) · Physica Medica · doi:10.1016/j.ejmp.2023.103166 · Cited by 29
EANM enabling guide: how to improve the accessibility of clinical dosimetry
Gear, J. I., Stokke, C., Terwinghe, C. Y., Gnesin, S., Sandström, M., Tran‐Gia, J., Cremonesi, M., Cicone, F., Verburg, F., Hustinx, R., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06226-z · Cited by 32
Radioligand therapies in meningioma: Evidence and future directions
Mair, M. J., Tabouret, É., Johnson, D. R., Sulman, E. P., Wen, P. Y., Preusser, M., & Albert, N. L. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae069 · Cited by 34
Currently available treatment options for neuroendocrine liver metastases
Machairas, N., Daskalakis, K., Felekouras, E., Alexandraki, K. I., Kaltsas, G., & Sotiropoulos, G. C. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0574 · Cited by 31
Roosen, J., Gotby, L. E. L. W., Arntz, M. J., Fütterer, J. J., Janssen, M. J. R., Konijnenberg, M., van Wijk, M. W. M., Overduin, C. G., & Nijsen, J. F. W. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05902-w · Cited by 30
“Treatment personalization is one of the key advances to be made to improve treatment efficacy in the upcoming years, not only in TARE [11], but also in other radionuclide therapies such as [177Lu]Lu-PSMA [18] or [177Lu]Luoctreotate radioligand therapy [19].”
BackgroundHallqvist, A., Brynjarsdóttir, E., Krantz, T., Sjögren, M., Svensson, J., & Bernhardt, P. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268902 · Cited by 29
“Strategies to optimize treatment ef fi cacy include modifying the number of treatment cycles or adjusting the administered activity based on the absorbed doses to critical organs, such as the kidneys ( 3 – 5 ).”
The next generation of peptide receptor radionuclide therapy
Brabander, T., Nonnekens, J., & Hofland, J. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0186 · Cited by 26
Quality of life in patients with midgut NET following peptide receptor radionuclide therapy
Marinova, M., Mücke, M., Fischer, F., Essler, M., Cuhls, H., Radbruch, L., Ghaei, S., Conrad, R., & Ahmadzadehfar, H. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04431-3 · Cited by 26
Peterson, A. B., Wang, C.-S., Wong, K.-K., Frey, K., Muzik, O., Schipper, M., & Dewaraja, Y. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004599 · Cited by 14
Waldeck, K., Zuylekom, J. V., Cullinane, C. M., Gulati, T., Simpson, K. J., Tothill, R. W., Blyth, B. J., & Hicks, R. J. (2023) · Theranostics · doi:10.7150/thno.84628 · Cited by 24
Sistani, G., Sutherland, D. E. K., Mujoomdar, A., Wiseman, D. P., Khatami, A., Tsvetkova, E. V., Reid, R. H., & Laidley, D. T. (2020) · Current Oncology · doi:10.3390/curroncol28010015 · Cited by 25
“Administering a fixed dose to all patients may cause significant toxicity resulting in loss of PRRT advantage in regard to better tolerability to alternatives [35].”
BackgroundKristiansson, A., Örbom, A., Timmermand, O. V., Ahlstedt, J., Strand, S., & Åkerström, B. (2021) · Antioxidants · doi:10.3390/antiox10081271 · Cited by 25
“Today, at least in PRRT and potentially in RLT, many patients are undertreated with the current therapeutic regime considering the relatively low toxicity seen in the kidneys and bone marrow, which are considered the dose limiting organs [57,58].”
BackgroundPeptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Santo, G., di Santo, G., & Virgolini, I. J. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.02.002 · Cited by 28
Maccauro, M., Cuomo, M., Bauckneht, M., Bagnalasta, M., Mazzaglia, S., Scalorbi, F., Argiroffi, G., Kirienko, M., Lorenzoni, A., Aliberti, G., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06863-y · Cited by 26
Läppchen, T., Bilinska, A., Pilatis, E., Menéndez, E., Imlimthan, S., Moon, E. S., Afshar‐Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2024) · Molecules · doi:10.3390/molecules29133093 · Cited by 27
Deshayes, E., Assénat, E., Meignant, L., Bardiès, M., Santoro, L., & Gourgou, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-10443-4 · Cited by 24
Overview and Current Status of Peptide Receptor Radionuclide Therapy
Bushnell, D. L., & Bodeker, K. L. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.11.005 · Cited by 25
Quantitative SPECT/CT—Technique and Clinical Applications
Ritt, P., & Kuwert, T. (2020) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-42618-7_17 · Cited by 21
Bushnell, D. L., Bodeker, K. L., O’Dorisio, T. M., Madsen, M. T., Menda, Y., Graves, S. A., Zamba, G. K. D., & O'Dorisio, M. S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254987 · Cited by 21
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
Sundlöv, A., & Gleisner, K. S. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.10.020 · Cited by 20
Opalińska, M., Sowa‐Staszczak, A., Grochowska, A., Olearska, H., & Hubalewska–Dydejczyk, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687925 · Cited by 22
Walrand, S., & Jamar, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158326 · Cited by 19
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
Beauregard, J. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00505-y · Cited by 25
Self-citationChicheportiche, A., Sason, M., Zidan, M., Godefroy, J., Krausz, Y., Gross, D. J., Grozinsky‐Glasberg, S., & Ben‐Haim, S. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264923 · Cited by 21
Vorster, M., Hadebe, B., & Sathekge, M. M. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1236565 · Cited by 19
Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems
Desy, A., Bouvet, G. F., Croteau, É., Lafrenière, N., Turcotte, É. E., Després, P., & Beauregard, J. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00421-3 · Cited by 19
“This issue was suspected in few of our patients treated with high activities (> 20 GBq) of 177Lu-octreotate and exhibiting high tumour retention in our personalized peptide receptor radionuclide therapy regimen [2].”
BackgroundSelf-citationŞimşek, D. H., Güzel, Y., Denizmen, D., Şanlı, Y., Büyükkaya, F., Kovan, B., Kömek, H., Işık, E. G., Özkan, Z. G., & Kuyumcu, S. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06497-6 · Cited by 18
Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy
Kennedy, J. A., Chicheportiche, A., & Keidar, Z. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.004 · Cited by 19
Olmo-García, M. I. D., Prado-Wohlwend, S., Andrés, A. T., Soriano, J. M., Belló, P., & Merino-Torres, J. F. (2021) · Biomedicines · doi:10.3390/biomedicines9121810 · Cited by 17
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
Desy, A., Bouvet, G. F., Frezza, A., Després, P., & Beauregard, J. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00303-0 · Cited by 20
Self-citationRichter, S., Steenblock, C., Fischer, A., Lemm, S., Ziegler, C. G., Bechmann, N., Nölting, S., Pietzsch, J., & Ullrich, M. (2023) · Theranostics · doi:10.7150/thno.87345 · Cited by 19
“…radiopharmaceutical can be improved by (i) optimizing treatment schemes and sequences, e.g., via personalized fractionating and dosing [49]; (ii) minimizing off-target retention, in particular in kidneys, thereby allowing for increased total applied doses of the radiopharmaceutical…”
BackgroundStrosberg, J., Hofman, M. S., Al‐Toubah, T., & Hope, T. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267167 · Cited by 20
Somatostatin receptor radionuclide therapy in neuroendocrine tumors
Haider, M., Das, S., Al‐Toubah, T., Pellè, E., El-Haddad, G. E., & Strosberg, J. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0360 · Cited by 19
“In one study, such a strategy enabled 50% of patients to receive more than four cycles (>29.6 GBq) of 177Lu-DOTATATE (Del Prete et al. 2019).”
BackgroundInfluentialDerlin, T., Bogdanova, N. V., Ohlendorf, F., Ramachandran, D., Werner, R. A., Roß, T. L., Christiansen, H., Bengel, F. M., & Henkenberens, C. (2021) · Cancers · doi:10.3390/cancers13071516 · Cited by 17
“Other groups have suggested PRRT based on individual dosimetry [35], which may become the standard of care and provide potential advantages over fixed-activity empiric PRRT.”
BackgroundMinczeles, N. S., de Herder, W. W., Konijnenberg, M., Feelders, R. A., Brabander, T., & Hofland, J. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004203 · Cited by 18
Malcolm, J., Falzone, N., Gains, J. E., Aldridge, M. D., Mirando, D. M., Lee, B. Q., Gaze, M. N., & Vallis, K. A. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00436-4 · Cited by 18
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy
Yadav, S., Lawhn-Heath, C. A., Paciorek, A. T., Lindsay, S., Mirro, R., Bergsland, E. K., & Hope, T. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266614 · Cited by 15
Clinical Pharmacology of Radiotheranostics in Oncology
Beek, E. T. T., Burggraaf, J., Teunissen, J. J. M., & Vriens, D. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2598 · Cited by 17
Minczeles, N. S., de Herder, W. W., Feelders, R. A., Verburg, F. A., Hofland, J., & Brabander, T. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263856 · Cited by 16
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Minczeles, N. S., Hofland, J., de Herder, W. W., & Brabander, T. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01037-7 · Cited by 16
Kurkowska, S., Brosch-Lenz, J., Dewaraja, Y. K., Frey, E. C., Sunderland, J. J., & Uribe, C. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268612 · Cited by 19
Staanum, P. F. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00561-8 · Cited by 15
Kayal, G., Roseland, M. E., Wang, C., Fitzpatrick, K., Mirando, D. M., Suresh, K., Wong, K. K., & Dewaraja, Y. K. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269389 · Cited by 15
Singh, S., Hope, T. A., Bergsland, E. B., Bodei, L., Bushnell, D. L., Chan, J. A., Chasen, B., Chauhan, A., Das, S., Dasari, A. N., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad096 · Cited by 15
Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
Nautiyal, A., Michopoulou, S. K., & Guy, M. (2023) · Clinical and Translational Imaging · doi:10.1007/s40336-023-00589-x · Cited by 15
“Generally, blood samples or imaging are used to estimate marrow dose [34, 37, 72].”
Moraitis, A., Küper, A. T., Tran‐Gia, J., Eberlein, U., Chen, Y., Seifert, R., Shi, K., Kim, M., Herrmann, K., Costa, P. F., et al. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.06.003 · Cited by 14
Dieudonné, A., Bailly, C., Cachin, F., Edet‐Sanson, A., Kraeber‐Bodéré, F., Hapdey, S., Merlin, C., Robin, P., Salaün, P., Schwartz, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06568-8 · Cited by 14
“Another study has implemented a treatment regimen based on renal dosimetry [27] by increasing the injected activity up to the presumed maximum tolerated renal absorbed dose, which did not improve the PFS compared to the aforementioned studies.”
ResultHou, X., Zhao, W., Beauregard, J., & Celler, A. M. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab32a1 · Cited by 14
Self-citationSui, H., Guo, F., Liu, H., Wang, R., Li, L., Wang, J., Jia, C., Xiang, J., Liang, Y., Chen, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.012 · Cited by 14
“The established tolerance absorbed-dose limit for the kidneys was 23 Gy 30 .”
Danieli, R., Mileva, M., Marin, G., Kristanto, P., Delbart, W., Vanderlinden, B., Wimana, Z., Hendlisz, A., Levillain, H., Reynaert, N., et al. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01163-w · Cited by 12
Cicone, F., Gleisner, K. S., Sarnelli, A., Indovina, L., Gear, J. I., Gnesin, S., Kraeber‐Bodéré, F., Delaloye, A. B., Valentini, V., & Cremonesi, M. (2023) · Physica Medica · doi:10.1016/j.ejmp.2023.103188 · Cited by 13
Fele‐Paranj, A., Saboury, B., Uribe, C., & Rahmim, A. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00236-w · Cited by 10
Yadav, S., Jiang, F., Kurkowska, S., Saelee, R., Morley, A., Feng, F. Y.-C., Aggarwal, R. R., Lawhn-Heath, C. A., Uribe, C., & Hope, T. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267208 · Cited by 11
Molecular imaging and radionuclide therapy of neuroendocrine tumors
Haider, M., Al‐Toubah, T., El-Haddad, G. E., & Strosberg, J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000519 · Cited by 10
“[53] recently reported results of a prospective personalized PRRT trial, in which the injected activity was adjusted to deliver a prescribed dose to the kidneys instead of a simulated fixed dose.”
Backgroundde Vries–Huizing, D. M. V., Versleijen, M. W. J., Sinaasappel, M., Walraven, I., Geluk–Jonker, M. M., Tesselaar, M. E. T., Hendrikx, J. J. M. A., der Veen, B. J. D. W., & Stokkel, M. P. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260073 · Cited by 12
Do we need dosimetry for the optimization of theranostics in CNS tumors?
Cicone, F., Gnesin, S., Santo, G., Stokke, C., Bartolomei, M., Cascini, G. L., Minniti, G. C., Paganelli, G., Verger, A., & Cremonesi, M. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae200 · Cited by 8
Bodei, L., Gnanasegaran, G., Giammarile, F., Pavel, M., Ambrosini, V., Baum, R. P., Hörsch, D., Howe, J. R., Cremonesi, M., El-Haddad, G., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100017 · Cited by 10
Nilica, B., Svirydenka, A., Fritz, J., Bayerschmidt, S., Kroiss, A. S., Gruber, L. N., & Virgolini, I. J. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2021.04.007 · Cited by 12
Metadata
- Authors
- Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M.
- Affiliations
- Université Laval (CA)
- Centre hospitalier universitaire de Québec (CA)
- Corresponding author
- Beauregard, Jean-Mathieu
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2018-11-30
- Volume
- 46
- Issue
- 3
- Pages
- 728-742
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2902656640
- Cited by
- 184
- References
- 26
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 28 · 2023: 34 · 2022: 31 · 2021: 28 · 2020: 13 · 2019: 9 · 2018: 1
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-142233)
- Fonds de Recherche du Québec - Santé
- Ministère de l'éducation et de l’enseignement supérieur du Québec
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- peptide receptor radionuclide therapy, 177Lu-octreotate, personalized dosimetry, glomerular filtration rate, renal dysfunction, neuroendocrine tumors, SPECT/CT dosimetry, treatment response, quality of life, hematologic toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Intestinal Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Radiometry, Safety, Stomach Neoplasms, Receptors, Peptide, Neuroendocrine Tumors, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.